Expert Comments:

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1 (6/13/18) Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. read more >
	André Uddin, Mackie Research Capital (3/14/18) "We are maintaining our Speculative Buy rating and our target price of $0.70 on ProMIS Neurosciences Inc. . .the company plans to initiate a single ascending dose, Phase 1 trial with PMN310 in 2019. It is also seeking to forge partnerships with big pharmas for other pipeline candidates."
André Uddin, Mackie Research Capital (1/23/18) "ProMIS Neurosciences Inc. reported that its PMN310 demonstrated significantly greater binding to toxic amyloid beta oligomers than Biogen's aducanumab in preclinical studies, a positive signal for better efficacy. . .we believe a licensing deal could come in as early as 2018. . .we are maintaining our Speculative Buy rating and increasing our target price to CA$0.70 from CA$0.50 previously."
Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's' (1/10/18) André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug. read more >
André Uddin, Mackie Research Capital (1/4/18) "ProMIS Neurosciences Inc. reported that PMN310 demonstrated no amyloid beta plaque binding in preclinical studies, a positive signal for improved safety. . .in terms of preclinical safety, PMN310 appears to be better than Biogen's aducanumab, which should facilitate a potential licensing deal for PMN310. We believe a licensing deal could come in as early as 2018."
André Uddin, Mackie Research Capital (11/13/17) "ProMIS Neurosciences Inc.'s fully diluted Q3/17 EPS of $0.01 compared to $0 last year. . .as of Q3/17E, the company had $3.3M in cash and zero debt on its balance sheet. . .we are maintaining our Speculative Buy rating and target price of CA$0.50/share."
André Uddin, Mackie Research Capital (10/17/17) "ProMIS Neurosciences Inc. announced that its lead Alzheimer's monoclonal antibody (mAb) candidate, PMN310, showed a high degree of selectivity to target amyloid beta oligomers when compared to other amyloid beta-directed mAbs in a preclinical study. . .given the favorable preclinical results, we remain confident that PMN310 should have better efficacy and safety than Biogen's aducanumab and [that] PMN310 has best-in-class potential to treat Alzheimer's."
André Uddin, Mackie Research Capital (9/19/17) "We are initiating coverage of Promis Neurosciences Inc. . .a promising new path for targeting Alzheimer's (AD). A therapy to treat the underlying cause of Alzheimer's disease represents an enormous market opportunity. . .Promis' lead mAb (monoclonal antibody) drug candidate, PMN310, was rationally designed to target toxic amyloid beta (AB) oligomers. AB is a “sticky” peptide (monomer) which clumps together to form toxic oligomers, which can in turn form plaque deposits. . .this newer theory is strongly backed by the Phase 1b success of Biogen's aducanumab which targets toxic AB oligomers. . .we believe this newer AD theory creates a path to develop a unique disease-modifying Alzheimer's treatment, PMN310 which has best-in-class potential."

More Expert Comments

	Douglas Loe, Echelon Wealth Partners (9/13/17) "ProMIS Neurosciences Inc. announced that a third therapy has been identified for the firm's Alzheimer's disease pipeline. The asset in question is PMN330, a mAb targeting amyloid-beta oligomers, and we assume the mAb is one of many based on CSO Neil Cashman's expertise in developing mAbs that target misfolded protein antigens. . .the asset will join two other identified lead compounds PMN310 and PMN350, with PMN310 still set to be the first lead asset to enter formal clinical trials by 2019."
	Eden Rahim, Next Edge Capital (4/5/17) "ProMIS Neurosciences Inc. is a preclinical company, but it will be going in the clinic over the next year or so. I'm in it because of some of the really important insights it has discovered into the mechanism of action of Alzheimer's disease. What ProMIS has discovered is that the ideal thing to target for Alzheimer's is soluble amyloid beta oligomers. It believes that they are the root cause of Alzheimer's, not the plaque that ultimately settles on the brain. ProMIS has discovered that by focusing on IgG 4 isotype, you can circumvent the inflammation that often comes with monoclonal antibodies. ProMIS has identified six epitopes on protein strains of misfolded amyloid precursor proteins (APPs). APPs are the misfolded proteins that eventually lead to something called fibrils, which eventually clot and form plaques in the brain. ProMIS has discovered that the prion strains of those misfolded proteins carry a marker, called an epitope. It's like a police car with a light on top. ProMIS has developed five murine antibodies that select for those epitopes so antibodies can find them on those misfolded proteins and bind to them. It is actually a pretty profound breakthrough at this level. Again, it's very early stage and preclinical. But ProMIS has selected one of those five antibodies. The drug that it's going to advance, PMN-310, will be its first candidate in clinic. I bought into ProMIS on a financing in the summer of 2015. I'll probably hold it for another 5 or 10 years. It's achieved a lot with very little, and its understanding of the mechanism of action of Alzheimer's is quite significant. I think we'll hear about that over the course of 2017." read more >

Experts Following This Company

	Douglas Loe, Analyst – Echelon Wealth Partners
	André Uddin – Mackie Research Capital

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.